Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

October 2017

Specialty Pharmacy Program Updates

Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications:

Specialty Pharmacy Program Updates



Available From

Tremfya (guselkumab)

Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CVS Specialty

Haegarda (C1 esterase inhibitor subcutaneous [Human])

To prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

CVS Specialty

Kevzara (sarilumab)

Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).

CVS Specialty

Tymlos (abaloparatide)

Treatment of postmenopausal women with osteoporosis who are at high risk for fracture.

CVS Specialty

Vosevi (sofosbuvir, velpatasvir, and voxilaprevir)

Treatment of adults with chronic HCV infection without cirrhosis or with compensated cirrhosis.

CVS Specialty

Idhifa (enasidenib)

Treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved

Non-mandatory: CVS Specialty

Benlysta SQ (belimumab)

Treatment of adults with active, autoantibody-positive, systemic
lupus erythematosus who are receiving standard therapy.

CVS Specialty

Mavyret (glecaprevir and pibrentasvir)

Treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). Also, the treatment of adults with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

CVS Specialty

Siliq (brodalumab)

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

CVS Specialty

Nerlynx (neratinib)

Treatment for adults who have early stage HER2-overexpressed/amplified breast cancer; used following treatment with Herceptin (trastuzumab).

Non-mandatory: CVS Specialty

Nityr (nitisinone)

Treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Limited Distribution: Diplomat Pharmacy

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


Harvard Pilgrim’s New “Estimate My Cost” Transparency Tool

Medicare Advantage: Important Information about Jimmo Settlement

Medicare Advantage Policy Updates for 2018

New Products and Benefits for 2018


Prior Authorization for Hip, Knee, and Shoulder Surgeries

Updates to Cholecystectomy Medical Review Criteria

Synagis for Upcoming RSV Season

Therapeutic Yoga for Chronic Pain and Other Conditions

P&T Committee Updates

Specialty Pharmacy Program Updates

ADHD Diagnosis and Follow-up Care


Reporting Modifier 50 for Bilateral Procedures

2018 CPT and HCPCS codes


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Senior Vice President, Network Strategy

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator